Welcome to our dedicated page for Prelude Therapeutics Incorporated news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics Incorporated stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies targeting key mechanisms in cancers with high unmet needs. Founded in 2016 and headquartered in Wilmington, Delaware, the company's mission is to deliver precision oncology treatments that can address the critical pathways in cancer cells.
Prelude's robust pipeline includes several promising drug candidates currently in clinical development:
- PRT543: This candidate is in Phase 1 clinical trials targeting select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies.
- PRT811: Also in Phase 1 trials, PRT811 focuses on solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.
- PRT1419: A potent and selective inhibitor of the anti-apoptotic protein MCL1, which is undergoing clinical evaluation for its efficacy and safety in cancer treatment.
- PRT2527: This highly selective CDK9 inhibitor demonstrates substantial potential in treating solid and hematological malignancies and aims to minimize off-target toxicities.
- PRT3645: A next-generation CDK4/6 inhibitor that shows promise for better safety, tolerability, and efficacy in various cancers beyond breast cancer.
- PRT3789: A first-in-class SMARCA2 protein degrader targeting cancers with SMARCA4 mutations.
In recent developments, Prelude has extended its cash runway into 2026 following a successful public offering, raising approximately $113 million in gross proceeds. Their strategic collaboration with AbCellera aims to co-develop innovative antibody drug conjugate therapies, combining AbCellera's antibody discovery platform with Prelude's expertise in medicinal chemistry and drug development.
Prelude's financial strength is evident with cash, cash equivalents, and marketable securities totaling $255 million as of June 30, 2023. Their focused approach on advancing their pipeline and making critical strategic decisions is supported by clinical data showing promising efficacy and safety profiles for their drug candidates, such as PRT2527 and PRT1419. The company's commitment to addressing cancers with high unmet needs positions it as a significant player in precision oncology.
For more detailed information and the latest updates on Prelude Therapeutics' research advancements, financial performance, and strategic initiatives, visit their official website and follow them on LinkedIn and Twitter.
Prelude Therapeutics (Nasdaq: PRLD) has announced the publication of an abstract for their novel SMARCA2 degrader, PRT3789, to be presented at the ESMO Congress 2024. The presentation will showcase the first clinical data for this highly-selective compound in patients with advanced solid tumors harboring SMARCA4 mutations.
Key points from the abstract include:
- 40 patients enrolled across various cancer types
- No dose-limiting toxicities or drug-related serious adverse events reported
- Dose-dependent decreases in SMARCA2 levels observed
- Clinical activity noted, including partial responses and tumor shrinkage
Prelude will host an investor webcast on September 13, 2024, to discuss the updated data presented at ESMO.
Prelude Therapeutics (NASDAQ: PRLD) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
- Interim Phase 1 data for PRT3789, a first-in-class IV SMARCA2 degrader, selected for oral presentation at ESMO 2024
- Received FDA IND authorization for PRT7732, a first-in-class oral SMARCA2 degrader
- Announced clinical collaboration with Merck to evaluate PRT3789 with KEYTRUDA in SMARCA4-mutated cancers
- CDK9 inhibitor PRT2527 on track to report interim Phase 1 data in Q4 2024
- Cash runway into 2026 with $179.8 million as of June 30, 2024
Q2 2024 financials: R&D expenses increased to $29.5 million, G&A expenses rose to $7.7 million, and net loss was $34.7 million ($0.46 per share).
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential of this combination to enhance anti-tumor activity due to the complementary mechanisms of the two treatments. Prelude will sponsor the trial, while Merck will supply KEYTRUDA. PRT3789 is in Phase 1 development for SMARCA4 mutant patients, with dose escalation expected to conclude mid-2024. Early pre-clinical data indicated promising anti-tumor immunity and tumor regression when combining SMARCA2 degraders with anti-PD-1 therapies. Both companies retain commercial rights to their respective treatments.
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in two notable healthcare conferences this June. CEO Kris Vaddi will engage in a fireside chat at the Jefferies Global Healthcare Conference on June 6th at 1:30 p.m. ET. Additionally, Dr. Vaddi will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12th at 10:40 a.m. ET. Both events will be webcast live and archived on the company's website for 90 days.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) will participate in the Citizens JMP Life Sciences Conference in New York City on May 13 and 14. The Company's CEO and Chief Medical Officer will engage in a fireside chat, with a live webcast accessible on their website. The event aims to showcase the company's developments in precision oncology.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported its financial results for the first quarter of 2024, highlighting progress in clinical development of lead drug candidates, PRT3789 and PRT2527. Operational leadership was strengthened by new hires. The company's cash runway extends into 2026 with $201.9 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
FAQ
What is the current stock price of Prelude Therapeutics Incorporated (PRLD)?
What is the market cap of Prelude Therapeutics Incorporated (PRLD)?
What does Prelude Therapeutics Incorporated specialize in?
Where is Prelude Therapeutics Incorporated based?
What are some key drug candidates in Prelude Therapeutics' pipeline?
What is PRT2527?
What recent financial achievement has Prelude Therapeutics reported?
Who has Prelude Therapeutics partnered with for drug development?
What is PRT3645?
What is the focus of PRT3789?
What are the financial resources available to Prelude Therapeutics?
Where can I find more information about Prelude Therapeutics?
